



KAZAKHSTAN

CDC Division of Global HIV & TB's Strategic Focus



The U.S. Centers for Disease Control and Prevention (CDC) and the Government of Kazakhstan (GOK) began their partnership in 1995 with the goal of strengthening the capacity to detect, treat, and prevent diseases and respond to public health threats in Central Asia. In 2005, CDC began implementing activities supported by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). To help build a sustainable HIV response, CDC supports the Kazakh Scientific Center for Dermatology and Infectious Diseases (KSCDID) to implement interventions and activities focused on people at greater risk of HIV.

CDC implements evidence-based intervention programs for people at greater risk of HIV, and these programs are rolled out to other regions of the country. CDC also provides technical assistance to the Ministry of Health in areas such as HIV care and treatment, counseling and testing, prevention, laboratory strengthening, and strategic information.

Key Activities and Accomplishments

Building Public Health Capacity

- Provided scientific expertise to update and implement the National Road Map 2023-2026.
- Supported KSCDID in improving the quality of a nationwide online electronic HIV case management system used by all HIV health facilities. The system offers reliable, real-time data on the HIV epidemic to guide informed clinical and program decisions.
- Delivered scientific expertise for piloting a biobehavioral survey for people at greater risk of HIV. This survey helps to understand trends in the HIV epidemic, including HIV prevalence and the interrelated behavioral dynamics.

Strengthening Laboratory Systems and Networks

- Supported external quality assurance assessments by providing proficiency panels in all 20 HIV laboratories in the country.

HIV Prevention and Treatment

- Supported five HIV health facilities that provide treatment services to 5,234 people living with HIV (PLHIV) in FY2024—an increase of nearly 34 percent from FY2019.
- Provided effective HIV treatment (e.g., Tenofovir, Lamivudine, and Dolutegravir) to more than 20,000 PLHIV in collaboration with the GOK. The GOK covers 95 percent of the HIV program's costs, including medicines.
- Scaled pre-exposure prophylaxis (PrEP) in Kazakhstan, covering 12,303 patients with PrEP in FY2024.
- Ensured continuous quality improvement for HIV care and treatment services through management and routine clinical visits to CDC-supported sites.
- Established a nurse-led HIV treatment and adherence program for people at greater risk of HIV, providing home-based follow-up for clients who are not virally suppressed. This program has led to a significant increase, with more than 92 percent of enrollees across all PEPFAR sites now virally suppressed.

CDC Country Representative:
Ramona Bhatia

Global HIV Epidemic

Estimated HIV Prevalence (Ages 15-49):
0.3% (2023)

Estimated HIV Deaths (Age ≥15):
Not Available

**Reported Number Receiving
Antiretroviral Therapy (ART) (Age ≥15):**
28,855 (2023)

Global Tuberculosis (TB) Epidemic

Estimated TB Incidence:
70/100,000 population (2023)

**Reported Percent of People with TB
and HIV: 6.2% (2023)**

TB Treatment Success Rate:
90% (2022)